Did you miss one of our webinars? Simply select the appropriate link below and view the recorded webinar. It will not be interactive, but you will see the chat questions the original attendees asked. For additional information on the products discussed in the webinar, explore our links to videos and other resources.
If there is an area you would like to see covered, you can request a topic of your choice.
If you are experiencing issues opening the webinar recordings, please be sure that you have the latest Adobe Flash Player installed.
Tuesday, June 13, 2017
Sergei Saveliev, PhD
Non-enzymatic post-translational modifications (PTMs) spontaneously occur in biotherapeutic proteins during manufacturing and storage. These modifications negatively affect efficacy and stability of biotherapeutic proteins. Major non-enzymatic PTMs are deamidation, disulfide bond scrambling and oxidation. These non-enzymatic PTMs are also introduced during protein preparation for peptide mapping and compromise the analysis. In the webinar recording Dr. Saveliev discusses sources of these artificial protein modifications as well as procedural optimizations to suppress these PTMs.
Tuesday, April 11, 2017
Hicham Zegzouti, PhD
Post-translational modifications (PTMs), the addition of functional groups to proteins, play a significant role in regulating cellular biology. Examples include phosphorylation, a common mechanism in regulating enzymatic activity, and the addition of carbohydrates to many eukaryotic proteins, which promotes proper folding, improves stability and serves in regulatory functions. A key objective of research and drug discovery surrounding PTMs is to study the regulation of these enzymes and find specific modulators of their activity. Although mass spectrometry, eastern and western blotting detection technologies have been used traditionally, none are amenable to high throughput or as sensitive as bioluminescent detection of nucleotide-based substrates for such enzymes.
Tuesday, March 28, 2017
Zhijie Jey Cheng, PhD
Reporter gene assays for functional screening and development of antibody drug candidates are gaining popularity due to the significant advantages they offer over traditional methods that rely on human primary immune cells. We will discuss development of a series of MoA-based reporter gene bioassays for antibodies targeting co-inhibitory receptors, co-stimulatory receptors and combination bioassays that target immune checkpoint receptors.
Tuesday, March 14, 2017
Terry Riss, PhD
3D cell culture models present a challenge for using assay chemistries and imaging methods that were originally designed for measuring events from 2D monolayers of cells. In this webinar, we will present factors to consider when designing and optimizing assays applied to 3D cell culture models, case studies describing design of reagents to overcome the limitations inherent with detecting markers from large 3D culture models, and applications of novel real-time detection methods.
Tuesday, February 28, 2017
Brad Hook, PhD
MicroRNAs (miRNAs) are small-noncoding RNA molecules that regulate gene expression post-transcriptionally. Amplification and overexpression of individual oncomiRs (miRNAs associated with cancer) or genetic loss of tumor suppressor miRNAs are associated with human cancer and are sufficient to drive tumorigenesis in mouse models. A global decrease in miRNA levels has been observed in human cancers and linked to genetic and epigenetic alterations in components of the miRNA biogenesis machinery. Learn more about how to analyze miRNAs in human cancer cells as we present data on a two studies that use new novel assays to monitor cell health and purify total RNA (including miRNAs) from the same cells.